Status: Not yet recruiting
Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds
Platelet-based therapies have been used to treat bony and soft tissue effects for more than 30 years. Tropocells® Autologous Platelet-Rich Fibrin (PRF) is being used to treat chronic, non-healing wounds, of a variety of types. This will help determine the safety and effective use of PRF in the treatment of soft tissue defects.
Participants needed: 16
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Estar Medical dba Medical Technologies, LTDUpdated: Jan 6, 2026Locations: 3
Eligibility criteria
1. Male or female ≥ 18≤ 80 years of age 2. Chronic wounds present for at least t...
Exclusion Criteria [+18]